News | Stroke | July 12, 2017

SanBio Receives $20 Million Grant for Stroke Clinical Trial

ACTIsSIMA trial will assess safety and efficacy of stem cell product in patients with chronic motor impairments resulting from ischemic stroke

SanBio Receives $20 Million Grant for Stroke Clinical Trial

July 12, 2017 — SanBio Inc. recently announced it has been awarded a $20 million grant from the California Institute of Regenerative Medicine (CIRM) in support of its Phase 2b clinical trial for the treatment of chronic stroke (ACTIsSIMA), jointly sponsored with Sunovion Pharmaceuticals Inc.

CIRM is an agency of the State of California formed to accelerate the progress of regenerative medicine through a highly competitive grant program. Prospective grants are evaluated by an independent panel of the nation's top experts in regenerative medicine, as well as medical authorities on neurological disorders. The evaluation of this stroke program received CIRM's highest ranking of 1.

Stroke is the leading cause of acquired disability in the United States. Many patients suffer from permanent loss of function. After the first six months, the possibility for further recovery through traditional therapies is minimal. Sufferers from stroke disability impose a significant burden on the health care system.

“Today the CIRM Board approved two very different methods, using different kinds of stem cells, to address this need,” said Maria Millan, M.D., interim CEO and president of the agency. “By funding multiple shots on goal we believe that we have a better chance of finding a way to repair the damage caused by stroke and give people a better quality of life.”

The ACTIsSIMA (Allogeneic Cell Therapy for Ischemic Stroke to Improve Motor Abilities) clinical trial studies the safety and efficacy of SanBio’s proprietary cell-based product, SB623, in patients with chronic motor impairments resulting from ischemic stroke. Enrollment for the ACTIsSIMA study is expected to be complete in March 2018. Patients will be monitored for 12 months, with results reported in 2019. This trial follows its Phase 1/2a study, the results of which were reported in the journal Stroke last year.1

For more information: www.sanbio.com


Related Content

News | Stroke

May 28, 2025 — Siemens Healthineers has introduced the first mobile stroke unit (MSU) featuring the Somatom On.site head ...

Home May 28, 2025
Home
News | Stroke

May 21, 2025 — RapidAI recently announced new study findings that show RapidAI’s clinically deep algorithms deliver ...

Home May 21, 2025
Home
News | Stroke

April 17, 2025 — Adults younger than 50 years of age had more than double the risk of having a stroke from migraine or ...

Home April 17, 2025
Home
News | Stroke

On April 9, 2025, the world’s first multisector advocacy movement dedicated to stroke — the Global Stroke Action ...

Home April 15, 2025
Home
News | Stroke

March 3, 2025 — Genentech, a member of the Roche Group, recently announced that the U.S. Food and Drug Administration ...

Home March 04, 2025
Home
News | Stroke

Feb. 6, 2025 — New findings from the DiVERT Stroke clinical study showed women spent less time in the hospital, saw ...

Home February 07, 2025
Home
News | Stroke

Feb. 5, 2025 — Removing a clot blocking a medium- or small-sized artery in the brain mechanically is a safe treatment ...

Home February 07, 2025
Home
News | Stroke

Jan. 29, 2025 — Researchers at Ochsner Health, led by Hernan Bazan, MD, DFSVS, FACS, have developed a predictive model ...

Home January 30, 2025
Home
News | Stroke

Nov. 16, 2024 Anthos Therapeutics, Inc.recently presented new data at the American Heart Association (AHA) Scientific ...

Home November 18, 2024
Home
News | Stroke

Oct. 24, 2024 – Royal Philips and Medtronic Neurovascular have announced a strategic advocacy partnership. Delivering ...

Home October 24, 2024
Home
Subscribe Now